nodes	percent_of_prediction	percent_of_DWPC	metapath
Rabeprazole—CYP3A4—bone cancer	0.474	1	CbGaD
Rabeprazole—ABCG2—Carboplatin—bone cancer	0.0829	0.276	CbGbCtD
Rabeprazole—ABCG2—Cisplatin—bone cancer	0.0708	0.236	CbGbCtD
Rabeprazole—ABCG2—Doxorubicin—bone cancer	0.0475	0.158	CbGbCtD
Rabeprazole—ABCG2—Methotrexate—bone cancer	0.046	0.153	CbGbCtD
Rabeprazole—CYP2C9—Cisplatin—bone cancer	0.0263	0.0878	CbGbCtD
Rabeprazole—CYP2D6—Doxorubicin—bone cancer	0.0161	0.0538	CbGbCtD
Rabeprazole—CYP3A4—Doxorubicin—bone cancer	0.0103	0.0342	CbGbCtD
Rabeprazole—ABCG2—HIF-2-alpha transcription factor network—CITED2—bone cancer	0.00221	0.0681	CbGpPWpGaD
Rabeprazole—CYP1A2—Lidocaine metabolism—CYP3A4—bone cancer	0.00182	0.056	CbGpPWpGaD
Rabeprazole—Esomeprazole—CYP3A4—bone cancer	0.00164	0.351	CrCbGaD
Rabeprazole—ABCG2—HIF-1-alpha transcription factor network—CITED2—bone cancer	0.0013	0.04	CbGpPWpGaD
Rabeprazole—Pantoprazole—CYP3A4—bone cancer	0.00119	0.254	CrCbGaD
Rabeprazole—Omeprazole—CYP3A4—bone cancer	0.000969	0.207	CrCbGaD
Rabeprazole—CYP1A1—Oxidation by Cytochrome P450—CYP4V2—bone cancer	0.000939	0.0289	CbGpPWpGaD
Rabeprazole—ABCG2—Irinotecan Pathway—CYP3A4—bone cancer	0.00089	0.0274	CbGpPWpGaD
Rabeprazole—Lansoprazole—CYP3A4—bone cancer	0.000887	0.189	CrCbGaD
Rabeprazole—CYP1A1—Benzo(a)pyrene metabolism—CYP3A4—bone cancer	0.000858	0.0264	CbGpPWpGaD
Rabeprazole—CYP2C19—Oxidation by Cytochrome P450—CYP4V2—bone cancer	0.000768	0.0236	CbGpPWpGaD
Rabeprazole—CYP2D6—Codeine and Morphine Metabolism—CYP3A4—bone cancer	0.00071	0.0218	CbGpPWpGaD
Rabeprazole—CYP2D6—Oxidation by Cytochrome P450—CYP4V2—bone cancer	0.000707	0.0217	CbGpPWpGaD
Rabeprazole—CYP2C9—Oxidation by Cytochrome P450—CYP4V2—bone cancer	0.000701	0.0215	CbGpPWpGaD
Rabeprazole—CYP2C9—Arachidonate Epoxygenase / Epoxide Hydrolase—GSTP1—bone cancer	0.00067	0.0206	CbGpPWpGaD
Rabeprazole—CYP1A2—Aflatoxin B1 metabolism—CYP3A4—bone cancer	0.000669	0.0206	CbGpPWpGaD
Rabeprazole—CYP1A2—Oxidation by Cytochrome P450—CYP4V2—bone cancer	0.000599	0.0184	CbGpPWpGaD
Rabeprazole—CYP1A1—Fatty Acid Omega Oxidation—CYP3A4—bone cancer	0.000542	0.0166	CbGpPWpGaD
Rabeprazole—ABCG2—Fluoropyrimidine Activity—DHFR—bone cancer	0.000529	0.0163	CbGpPWpGaD
Rabeprazole—CYP1A1—Estrogen metabolism—CYP3A4—bone cancer	0.000493	0.0152	CbGpPWpGaD
Rabeprazole—CYP3A4—Oxidation by Cytochrome P450—CYP4V2—bone cancer	0.000462	0.0142	CbGpPWpGaD
Rabeprazole—CYP1A1—Xenobiotics—CYP3A4—bone cancer	0.000453	0.0139	CbGpPWpGaD
Rabeprazole—ATP4B—Transmembrane transport of small molecules—TUBB4B—bone cancer	0.000441	0.0136	CbGpPWpGaD
Rabeprazole—CYP1A1—Tamoxifen metabolism—CYP3A4—bone cancer	0.000436	0.0134	CbGpPWpGaD
Rabeprazole—CYP3A4—Drug Induction of Bile Acid Pathway—NR1I2—bone cancer	0.000435	0.0134	CbGpPWpGaD
Rabeprazole—CYP2D6—Fatty Acid Omega Oxidation—CYP3A4—bone cancer	0.000408	0.0125	CbGpPWpGaD
Rabeprazole—CYP1A1—Metapathway biotransformation—CYP4V2—bone cancer	0.000404	0.0124	CbGpPWpGaD
Rabeprazole—ATP4A—Transmembrane transport of small molecules—TUBB4B—bone cancer	0.000393	0.0121	CbGpPWpGaD
Rabeprazole—ATP4B—Transmembrane transport of small molecules—TUBB2A—bone cancer	0.000381	0.0117	CbGpPWpGaD
Rabeprazole—CYP2C9—Nuclear Receptors in Lipid Metabolism and Toxicity—NR1I2—bone cancer	0.000379	0.0116	CbGpPWpGaD
Rabeprazole—CYP2C19—Xenobiotics—CYP3A4—bone cancer	0.000371	0.0114	CbGpPWpGaD
Rabeprazole—CYP2C19—Tamoxifen metabolism—CYP3A4—bone cancer	0.000357	0.011	CbGpPWpGaD
Rabeprazole—CYP1A2—Fatty Acid Omega Oxidation—CYP3A4—bone cancer	0.000345	0.0106	CbGpPWpGaD
Rabeprazole—CYP2D6—Xenobiotics—CYP3A4—bone cancer	0.000341	0.0105	CbGpPWpGaD
Rabeprazole—ATP4A—Transmembrane transport of small molecules—TUBB2A—bone cancer	0.000339	0.0104	CbGpPWpGaD
Rabeprazole—CYP2C9—Xenobiotics—CYP3A4—bone cancer	0.000338	0.0104	CbGpPWpGaD
Rabeprazole—CYP2C19—Metapathway biotransformation—CYP4V2—bone cancer	0.000331	0.0102	CbGpPWpGaD
Rabeprazole—CYP2D6—Tamoxifen metabolism—CYP3A4—bone cancer	0.000328	0.0101	CbGpPWpGaD
Rabeprazole—CYP2C9—Tamoxifen metabolism—CYP3A4—bone cancer	0.000325	0.00999	CbGpPWpGaD
Rabeprazole—CYP1A2—Nuclear Receptors in Lipid Metabolism and Toxicity—NR1I2—bone cancer	0.000323	0.00994	CbGpPWpGaD
Rabeprazole—CYP1A2—Estrogen metabolism—CYP3A4—bone cancer	0.000314	0.00966	CbGpPWpGaD
Rabeprazole—CYP2D6—Metapathway biotransformation—CYP4V2—bone cancer	0.000304	0.00935	CbGpPWpGaD
Rabeprazole—CYP2C9—Metapathway biotransformation—CYP4V2—bone cancer	0.000301	0.00927	CbGpPWpGaD
Rabeprazole—CYP1A2—Aflatoxin activation and detoxification—CYP3A4—bone cancer	0.000301	0.00925	CbGpPWpGaD
Rabeprazole—CYP1A2—Xenobiotics—CYP3A4—bone cancer	0.000289	0.00888	CbGpPWpGaD
Rabeprazole—CYP1A2—Tamoxifen metabolism—CYP3A4—bone cancer	0.000278	0.00854	CbGpPWpGaD
Rabeprazole—CYP1A2—Metapathway biotransformation—CYP4V2—bone cancer	0.000258	0.00792	CbGpPWpGaD
Rabeprazole—CYP1A1—Estrogen Receptor Pathway—JUN—bone cancer	0.000255	0.00785	CbGpPWpGaD
Rabeprazole—CYP2C19—Constitutive Androstane Receptor Pathway—CYP3A4—bone cancer	0.000255	0.00783	CbGpPWpGaD
Rabeprazole—CYP3A4—Nuclear Receptors in Lipid Metabolism and Toxicity—NR1I2—bone cancer	0.00025	0.00767	CbGpPWpGaD
Rabeprazole—CYP1A1—Tryptophan metabolism—CYP3A4—bone cancer	0.000233	0.00715	CbGpPWpGaD
Rabeprazole—CYP2C9—Constitutive Androstane Receptor Pathway—CYP3A4—bone cancer	0.000232	0.00714	CbGpPWpGaD
Rabeprazole—CYP2C9—Nuclear Receptors in Lipid Metabolism and Toxicity—CYP3A4—bone cancer	0.000221	0.0068	CbGpPWpGaD
Rabeprazole—CYP3A4—Metapathway biotransformation—CYP4V2—bone cancer	0.000199	0.00611	CbGpPWpGaD
Rabeprazole—Angina pectoris—Doxorubicin—bone cancer	0.000193	0.00102	CcSEcCtD
Rabeprazole—Epistaxis—Methotrexate—bone cancer	0.000192	0.00102	CcSEcCtD
Rabeprazole—Pneumonia—Epirubicin—bone cancer	0.000192	0.00101	CcSEcCtD
Rabeprazole—ABCG2—Imatinib Resistance in Chronic Myeloid Leukemia—KIT—bone cancer	0.000191	0.00586	CbGpPWpGaD
Rabeprazole—Bronchitis—Doxorubicin—bone cancer	0.00019	0.00101	CcSEcCtD
Rabeprazole—Agranulocytosis—Methotrexate—bone cancer	0.00019	0.001	CcSEcCtD
Rabeprazole—Stevens-Johnson syndrome—Epirubicin—bone cancer	0.000189	0.000999	CcSEcCtD
Rabeprazole—CYP1A2—Nuclear Receptors in Lipid Metabolism and Toxicity—CYP3A4—bone cancer	0.000189	0.00581	CbGpPWpGaD
Rabeprazole—CYP1A1—Cytochrome P450 - arranged by substrate type—CYP3A4—bone cancer	0.000188	0.00578	CbGpPWpGaD
Rabeprazole—Pancytopenia—Doxorubicin—bone cancer	0.000188	0.000993	CcSEcCtD
Rabeprazole—Body temperature increased—Cisplatin—bone cancer	0.000187	0.000989	CcSEcCtD
Rabeprazole—Neuropathy peripheral—Epirubicin—bone cancer	0.000187	0.000988	CcSEcCtD
Rabeprazole—Jaundice—Epirubicin—bone cancer	0.000186	0.000982	CcSEcCtD
Rabeprazole—Stomatitis—Epirubicin—bone cancer	0.000186	0.000982	CcSEcCtD
Rabeprazole—CYP1A1—Oxidation by Cytochrome P450—CYP3A4—bone cancer	0.000186	0.00571	CbGpPWpGaD
Rabeprazole—Urinary tract infection—Epirubicin—bone cancer	0.000185	0.000979	CcSEcCtD
Rabeprazole—Conjunctivitis—Epirubicin—bone cancer	0.000185	0.000979	CcSEcCtD
Rabeprazole—Dysuria—Doxorubicin—bone cancer	0.000185	0.000978	CcSEcCtD
Rabeprazole—Neutropenia—Doxorubicin—bone cancer	0.000185	0.000978	CcSEcCtD
Rabeprazole—Hepatitis—Methotrexate—bone cancer	0.000183	0.000966	CcSEcCtD
Rabeprazole—Sweating—Epirubicin—bone cancer	0.000183	0.000966	CcSEcCtD
Rabeprazole—Pollakiuria—Doxorubicin—bone cancer	0.000183	0.000966	CcSEcCtD
Rabeprazole—Haematuria—Epirubicin—bone cancer	0.000182	0.000961	CcSEcCtD
Rabeprazole—Pharyngitis—Methotrexate—bone cancer	0.000181	0.000959	CcSEcCtD
Rabeprazole—Urinary tract disorder—Methotrexate—bone cancer	0.000181	0.000954	CcSEcCtD
Rabeprazole—Photosensitivity reaction—Doxorubicin—bone cancer	0.000181	0.000954	CcSEcCtD
Rabeprazole—Weight increased—Doxorubicin—bone cancer	0.00018	0.000952	CcSEcCtD
Rabeprazole—Epistaxis—Epirubicin—bone cancer	0.00018	0.00095	CcSEcCtD
Rabeprazole—Urethral disorder—Methotrexate—bone cancer	0.000179	0.000947	CcSEcCtD
Rabeprazole—Weight decreased—Doxorubicin—bone cancer	0.000179	0.000946	CcSEcCtD
Rabeprazole—Sinusitis—Epirubicin—bone cancer	0.000179	0.000945	CcSEcCtD
Rabeprazole—Hyperglycaemia—Doxorubicin—bone cancer	0.000178	0.000943	CcSEcCtD
Rabeprazole—Agranulocytosis—Epirubicin—bone cancer	0.000178	0.00094	CcSEcCtD
Rabeprazole—Pneumonia—Doxorubicin—bone cancer	0.000177	0.000938	CcSEcCtD
Rabeprazole—Visual impairment—Methotrexate—bone cancer	0.000176	0.000931	CcSEcCtD
Rabeprazole—Stevens-Johnson syndrome—Doxorubicin—bone cancer	0.000175	0.000924	CcSEcCtD
Rabeprazole—Hypersensitivity—Cisplatin—bone cancer	0.000174	0.000922	CcSEcCtD
Rabeprazole—Bradycardia—Epirubicin—bone cancer	0.000174	0.000921	CcSEcCtD
Rabeprazole—Erythema multiforme—Methotrexate—bone cancer	0.000173	0.000914	CcSEcCtD
Rabeprazole—Neuropathy peripheral—Doxorubicin—bone cancer	0.000173	0.000914	CcSEcCtD
Rabeprazole—Stomatitis—Doxorubicin—bone cancer	0.000172	0.000909	CcSEcCtD
Rabeprazole—Jaundice—Doxorubicin—bone cancer	0.000172	0.000909	CcSEcCtD
Rabeprazole—Rhinitis—Epirubicin—bone cancer	0.000172	0.000907	CcSEcCtD
Rabeprazole—Conjunctivitis—Doxorubicin—bone cancer	0.000171	0.000906	CcSEcCtD
Rabeprazole—Urinary tract infection—Doxorubicin—bone cancer	0.000171	0.000906	CcSEcCtD
Rabeprazole—Hepatitis—Epirubicin—bone cancer	0.000171	0.000904	CcSEcCtD
Rabeprazole—Eye disorder—Methotrexate—bone cancer	0.000171	0.000903	CcSEcCtD
Rabeprazole—Tinnitus—Methotrexate—bone cancer	0.00017	0.000901	CcSEcCtD
Rabeprazole—Asthenia—Cisplatin—bone cancer	0.00017	0.000898	CcSEcCtD
Rabeprazole—Pharyngitis—Epirubicin—bone cancer	0.00017	0.000898	CcSEcCtD
Rabeprazole—Sweating—Doxorubicin—bone cancer	0.000169	0.000894	CcSEcCtD
Rabeprazole—Urinary tract disorder—Epirubicin—bone cancer	0.000169	0.000893	CcSEcCtD
Rabeprazole—Oedema peripheral—Epirubicin—bone cancer	0.000169	0.000891	CcSEcCtD
Rabeprazole—Haematuria—Doxorubicin—bone cancer	0.000168	0.000889	CcSEcCtD
Rabeprazole—Urethral disorder—Epirubicin—bone cancer	0.000168	0.000887	CcSEcCtD
Rabeprazole—Epistaxis—Doxorubicin—bone cancer	0.000166	0.000879	CcSEcCtD
Rabeprazole—Angiopathy—Methotrexate—bone cancer	0.000166	0.000877	CcSEcCtD
Rabeprazole—Sinusitis—Doxorubicin—bone cancer	0.000165	0.000875	CcSEcCtD
Rabeprazole—Visual impairment—Epirubicin—bone cancer	0.000165	0.000872	CcSEcCtD
Rabeprazole—Agranulocytosis—Doxorubicin—bone cancer	0.000165	0.00087	CcSEcCtD
Rabeprazole—Chills—Methotrexate—bone cancer	0.000164	0.000867	CcSEcCtD
Rabeprazole—CYP1A2—Estrogen Receptor Pathway—JUN—bone cancer	0.000163	0.00501	CbGpPWpGaD
Rabeprazole—Diarrhoea—Cisplatin—bone cancer	0.000162	0.000856	CcSEcCtD
Rabeprazole—Erythema multiforme—Epirubicin—bone cancer	0.000162	0.000855	CcSEcCtD
Rabeprazole—Alopecia—Methotrexate—bone cancer	0.000162	0.000854	CcSEcCtD
Rabeprazole—Bradycardia—Doxorubicin—bone cancer	0.000161	0.000852	CcSEcCtD
Rabeprazole—Eye disorder—Epirubicin—bone cancer	0.00016	0.000845	CcSEcCtD
Rabeprazole—Tinnitus—Epirubicin—bone cancer	0.00016	0.000843	CcSEcCtD
Rabeprazole—Malnutrition—Methotrexate—bone cancer	0.000159	0.000841	CcSEcCtD
Rabeprazole—Erythema—Methotrexate—bone cancer	0.000159	0.000841	CcSEcCtD
Rabeprazole—Rhinitis—Doxorubicin—bone cancer	0.000159	0.000839	CcSEcCtD
Rabeprazole—Hepatitis—Doxorubicin—bone cancer	0.000158	0.000837	CcSEcCtD
Rabeprazole—Pharyngitis—Doxorubicin—bone cancer	0.000157	0.000831	CcSEcCtD
Rabeprazole—Urinary tract disorder—Doxorubicin—bone cancer	0.000156	0.000826	CcSEcCtD
Rabeprazole—Oedema peripheral—Doxorubicin—bone cancer	0.000156	0.000824	CcSEcCtD
Rabeprazole—Dysgeusia—Methotrexate—bone cancer	0.000156	0.000824	CcSEcCtD
Rabeprazole—Angiopathy—Epirubicin—bone cancer	0.000155	0.000821	CcSEcCtD
Rabeprazole—Urethral disorder—Doxorubicin—bone cancer	0.000155	0.00082	CcSEcCtD
Rabeprazole—Back pain—Methotrexate—bone cancer	0.000154	0.000814	CcSEcCtD
Rabeprazole—CYP2C19—Cytochrome P450 - arranged by substrate type—CYP3A4—bone cancer	0.000154	0.00473	CbGpPWpGaD
Rabeprazole—Chills—Epirubicin—bone cancer	0.000154	0.000812	CcSEcCtD
Rabeprazole—Arrhythmia—Epirubicin—bone cancer	0.000153	0.000808	CcSEcCtD
Rabeprazole—Visual impairment—Doxorubicin—bone cancer	0.000153	0.000806	CcSEcCtD
Rabeprazole—CYP1A1—Phase 1 - Functionalization of compounds—CYP3A4—bone cancer	0.000153	0.00469	CbGpPWpGaD
Rabeprazole—CYP2C19—Oxidation by Cytochrome P450—CYP3A4—bone cancer	0.000152	0.00467	CbGpPWpGaD
Rabeprazole—Alopecia—Epirubicin—bone cancer	0.000151	0.000799	CcSEcCtD
Rabeprazole—Vomiting—Cisplatin—bone cancer	0.000151	0.000796	CcSEcCtD
Rabeprazole—Vision blurred—Methotrexate—bone cancer	0.00015	0.000793	CcSEcCtD
Rabeprazole—Erythema multiforme—Doxorubicin—bone cancer	0.00015	0.000791	CcSEcCtD
Rabeprazole—Rash—Cisplatin—bone cancer	0.000149	0.000789	CcSEcCtD
Rabeprazole—Dermatitis—Cisplatin—bone cancer	0.000149	0.000788	CcSEcCtD
Rabeprazole—Erythema—Epirubicin—bone cancer	0.000149	0.000787	CcSEcCtD
Rabeprazole—Malnutrition—Epirubicin—bone cancer	0.000149	0.000787	CcSEcCtD
Rabeprazole—CYP1A2—Tryptophan metabolism—CYP3A4—bone cancer	0.000148	0.00456	CbGpPWpGaD
Rabeprazole—Eye disorder—Doxorubicin—bone cancer	0.000148	0.000782	CcSEcCtD
Rabeprazole—Ill-defined disorder—Methotrexate—bone cancer	0.000148	0.000781	CcSEcCtD
Rabeprazole—Tinnitus—Doxorubicin—bone cancer	0.000148	0.00078	CcSEcCtD
Rabeprazole—Anaemia—Methotrexate—bone cancer	0.000147	0.000778	CcSEcCtD
Rabeprazole—Flatulence—Epirubicin—bone cancer	0.000147	0.000776	CcSEcCtD
Rabeprazole—Tension—Epirubicin—bone cancer	0.000146	0.000773	CcSEcCtD
Rabeprazole—Dysgeusia—Epirubicin—bone cancer	0.000146	0.000771	CcSEcCtD
Rabeprazole—Nervousness—Epirubicin—bone cancer	0.000145	0.000765	CcSEcCtD
Rabeprazole—Back pain—Epirubicin—bone cancer	0.000144	0.000762	CcSEcCtD
Rabeprazole—Angiopathy—Doxorubicin—bone cancer	0.000144	0.000759	CcSEcCtD
Rabeprazole—Malaise—Methotrexate—bone cancer	0.000144	0.000759	CcSEcCtD
Rabeprazole—Muscle spasms—Epirubicin—bone cancer	0.000143	0.000757	CcSEcCtD
Rabeprazole—Vertigo—Methotrexate—bone cancer	0.000143	0.000756	CcSEcCtD
Rabeprazole—Leukopenia—Methotrexate—bone cancer	0.000142	0.000753	CcSEcCtD
Rabeprazole—Chills—Doxorubicin—bone cancer	0.000142	0.000751	CcSEcCtD
Rabeprazole—CYP2D6—Cytochrome P450 - arranged by substrate type—CYP3A4—bone cancer	0.000142	0.00435	CbGpPWpGaD
Rabeprazole—Arrhythmia—Doxorubicin—bone cancer	0.000141	0.000748	CcSEcCtD
Rabeprazole—Nausea—Cisplatin—bone cancer	0.000141	0.000743	CcSEcCtD
Rabeprazole—Vision blurred—Epirubicin—bone cancer	0.00014	0.000742	CcSEcCtD
Rabeprazole—CYP2C9—Cytochrome P450 - arranged by substrate type—CYP3A4—bone cancer	0.00014	0.00432	CbGpPWpGaD
Rabeprazole—Alopecia—Doxorubicin—bone cancer	0.00014	0.00074	CcSEcCtD
Rabeprazole—CYP2D6—Oxidation by Cytochrome P450—CYP3A4—bone cancer	0.00014	0.0043	CbGpPWpGaD
Rabeprazole—Cough—Methotrexate—bone cancer	0.000139	0.000734	CcSEcCtD
Rabeprazole—CYP2C9—Oxidation by Cytochrome P450—CYP3A4—bone cancer	0.000139	0.00426	CbGpPWpGaD
Rabeprazole—Ill-defined disorder—Epirubicin—bone cancer	0.000138	0.000731	CcSEcCtD
Rabeprazole—Convulsion—Methotrexate—bone cancer	0.000138	0.000729	CcSEcCtD
Rabeprazole—Malnutrition—Doxorubicin—bone cancer	0.000138	0.000729	CcSEcCtD
Rabeprazole—Erythema—Doxorubicin—bone cancer	0.000138	0.000729	CcSEcCtD
Rabeprazole—Anaemia—Epirubicin—bone cancer	0.000138	0.000728	CcSEcCtD
Rabeprazole—Agitation—Epirubicin—bone cancer	0.000137	0.000724	CcSEcCtD
Rabeprazole—Flatulence—Doxorubicin—bone cancer	0.000136	0.000718	CcSEcCtD
Rabeprazole—Chest pain—Methotrexate—bone cancer	0.000136	0.000716	CcSEcCtD
Rabeprazole—Myalgia—Methotrexate—bone cancer	0.000136	0.000716	CcSEcCtD
Rabeprazole—Arthralgia—Methotrexate—bone cancer	0.000136	0.000716	CcSEcCtD
Rabeprazole—Tension—Doxorubicin—bone cancer	0.000135	0.000715	CcSEcCtD
Rabeprazole—Dysgeusia—Doxorubicin—bone cancer	0.000135	0.000713	CcSEcCtD
Rabeprazole—Malaise—Epirubicin—bone cancer	0.000134	0.00071	CcSEcCtD
Rabeprazole—Discomfort—Methotrexate—bone cancer	0.000134	0.000708	CcSEcCtD
Rabeprazole—Nervousness—Doxorubicin—bone cancer	0.000134	0.000708	CcSEcCtD
Rabeprazole—Vertigo—Epirubicin—bone cancer	0.000134	0.000707	CcSEcCtD
Rabeprazole—Syncope—Epirubicin—bone cancer	0.000134	0.000706	CcSEcCtD
Rabeprazole—Leukopenia—Epirubicin—bone cancer	0.000133	0.000705	CcSEcCtD
Rabeprazole—Back pain—Doxorubicin—bone cancer	0.000133	0.000705	CcSEcCtD
Rabeprazole—Muscle spasms—Doxorubicin—bone cancer	0.000133	0.0007	CcSEcCtD
Rabeprazole—Palpitations—Epirubicin—bone cancer	0.000132	0.000696	CcSEcCtD
Rabeprazole—Confusional state—Methotrexate—bone cancer	0.000131	0.000692	CcSEcCtD
Rabeprazole—Loss of consciousness—Epirubicin—bone cancer	0.000131	0.000692	CcSEcCtD
Rabeprazole—Cough—Epirubicin—bone cancer	0.00013	0.000687	CcSEcCtD
Rabeprazole—Anaphylactic shock—Methotrexate—bone cancer	0.00013	0.000687	CcSEcCtD
Rabeprazole—Vision blurred—Doxorubicin—bone cancer	0.00013	0.000687	CcSEcCtD
Rabeprazole—Convulsion—Epirubicin—bone cancer	0.000129	0.000682	CcSEcCtD
Rabeprazole—Hypertension—Epirubicin—bone cancer	0.000129	0.00068	CcSEcCtD
Rabeprazole—Ill-defined disorder—Doxorubicin—bone cancer	0.000128	0.000676	CcSEcCtD
Rabeprazole—Anaemia—Doxorubicin—bone cancer	0.000127	0.000673	CcSEcCtD
Rabeprazole—Thrombocytopenia—Methotrexate—bone cancer	0.000127	0.000672	CcSEcCtD
Rabeprazole—Myalgia—Epirubicin—bone cancer	0.000127	0.00067	CcSEcCtD
Rabeprazole—Arthralgia—Epirubicin—bone cancer	0.000127	0.00067	CcSEcCtD
Rabeprazole—Chest pain—Epirubicin—bone cancer	0.000127	0.00067	CcSEcCtD
Rabeprazole—Agitation—Doxorubicin—bone cancer	0.000127	0.000669	CcSEcCtD
Rabeprazole—Anxiety—Epirubicin—bone cancer	0.000126	0.000668	CcSEcCtD
Rabeprazole—Hyperhidrosis—Methotrexate—bone cancer	0.000126	0.000664	CcSEcCtD
Rabeprazole—CYP1A1—Aryl Hydrocarbon Receptor—RB1—bone cancer	0.000125	0.00386	CbGpPWpGaD
Rabeprazole—Discomfort—Epirubicin—bone cancer	0.000125	0.000662	CcSEcCtD
Rabeprazole—CYP2C19—Phase 1 - Functionalization of compounds—CYP3A4—bone cancer	0.000125	0.00384	CbGpPWpGaD
Rabeprazole—Malaise—Doxorubicin—bone cancer	0.000124	0.000657	CcSEcCtD
Rabeprazole—Dry mouth—Epirubicin—bone cancer	0.000124	0.000656	CcSEcCtD
Rabeprazole—Vertigo—Doxorubicin—bone cancer	0.000124	0.000655	CcSEcCtD
Rabeprazole—Anorexia—Methotrexate—bone cancer	0.000124	0.000655	CcSEcCtD
Rabeprazole—Syncope—Doxorubicin—bone cancer	0.000124	0.000653	CcSEcCtD
Rabeprazole—Leukopenia—Doxorubicin—bone cancer	0.000123	0.000652	CcSEcCtD
Rabeprazole—Confusional state—Epirubicin—bone cancer	0.000123	0.000648	CcSEcCtD
Rabeprazole—Palpitations—Doxorubicin—bone cancer	0.000122	0.000644	CcSEcCtD
Rabeprazole—Oedema—Epirubicin—bone cancer	0.000122	0.000643	CcSEcCtD
Rabeprazole—Anaphylactic shock—Epirubicin—bone cancer	0.000122	0.000643	CcSEcCtD
Rabeprazole—Hypotension—Methotrexate—bone cancer	0.000121	0.000642	CcSEcCtD
Rabeprazole—Loss of consciousness—Doxorubicin—bone cancer	0.000121	0.00064	CcSEcCtD
Rabeprazole—Cough—Doxorubicin—bone cancer	0.00012	0.000636	CcSEcCtD
Rabeprazole—CYP1A2—Cytochrome P450 - arranged by substrate type—CYP3A4—bone cancer	0.00012	0.00369	CbGpPWpGaD
Rabeprazole—Shock—Epirubicin—bone cancer	0.00012	0.000632	CcSEcCtD
Rabeprazole—Convulsion—Doxorubicin—bone cancer	0.000119	0.000631	CcSEcCtD
Rabeprazole—Thrombocytopenia—Epirubicin—bone cancer	0.000119	0.000629	CcSEcCtD
Rabeprazole—Hypertension—Doxorubicin—bone cancer	0.000119	0.000629	CcSEcCtD
Rabeprazole—Tachycardia—Epirubicin—bone cancer	0.000119	0.000627	CcSEcCtD
Rabeprazole—CYP1A2—Oxidation by Cytochrome P450—CYP3A4—bone cancer	0.000118	0.00364	CbGpPWpGaD
Rabeprazole—Musculoskeletal discomfort—Methotrexate—bone cancer	0.000118	0.000626	CcSEcCtD
Rabeprazole—ABCG2—Fluoropyrimidine Activity—TP53—bone cancer	0.000118	0.00363	CbGpPWpGaD
Rabeprazole—Hyperhidrosis—Epirubicin—bone cancer	0.000118	0.000621	CcSEcCtD
Rabeprazole—Insomnia—Methotrexate—bone cancer	0.000118	0.000621	CcSEcCtD
Rabeprazole—Chest pain—Doxorubicin—bone cancer	0.000117	0.00062	CcSEcCtD
Rabeprazole—Arthralgia—Doxorubicin—bone cancer	0.000117	0.00062	CcSEcCtD
Rabeprazole—Myalgia—Doxorubicin—bone cancer	0.000117	0.00062	CcSEcCtD
Rabeprazole—Anxiety—Doxorubicin—bone cancer	0.000117	0.000618	CcSEcCtD
Rabeprazole—Paraesthesia—Methotrexate—bone cancer	0.000117	0.000617	CcSEcCtD
Rabeprazole—Discomfort—Doxorubicin—bone cancer	0.000116	0.000613	CcSEcCtD
Rabeprazole—Anorexia—Epirubicin—bone cancer	0.000116	0.000613	CcSEcCtD
Rabeprazole—Dyspnoea—Methotrexate—bone cancer	0.000116	0.000612	CcSEcCtD
Rabeprazole—Somnolence—Methotrexate—bone cancer	0.000115	0.00061	CcSEcCtD
Rabeprazole—CYP2D6—Phase 1 - Functionalization of compounds—CYP3A4—bone cancer	0.000115	0.00353	CbGpPWpGaD
Rabeprazole—Dry mouth—Doxorubicin—bone cancer	0.000115	0.000607	CcSEcCtD
Rabeprazole—Dyspepsia—Methotrexate—bone cancer	0.000114	0.000604	CcSEcCtD
Rabeprazole—CYP2C9—Phase 1 - Functionalization of compounds—CYP3A4—bone cancer	0.000114	0.0035	CbGpPWpGaD
Rabeprazole—Hypotension—Epirubicin—bone cancer	0.000114	0.0006	CcSEcCtD
Rabeprazole—Confusional state—Doxorubicin—bone cancer	0.000113	0.0006	CcSEcCtD
Rabeprazole—Decreased appetite—Methotrexate—bone cancer	0.000113	0.000597	CcSEcCtD
Rabeprazole—Anaphylactic shock—Doxorubicin—bone cancer	0.000112	0.000595	CcSEcCtD
Rabeprazole—Oedema—Doxorubicin—bone cancer	0.000112	0.000595	CcSEcCtD
Rabeprazole—Pain—Methotrexate—bone cancer	0.000111	0.000587	CcSEcCtD
Rabeprazole—Musculoskeletal discomfort—Epirubicin—bone cancer	0.000111	0.000585	CcSEcCtD
Rabeprazole—Shock—Doxorubicin—bone cancer	0.000111	0.000585	CcSEcCtD
Rabeprazole—Thrombocytopenia—Doxorubicin—bone cancer	0.00011	0.000582	CcSEcCtD
Rabeprazole—Insomnia—Epirubicin—bone cancer	0.00011	0.000581	CcSEcCtD
Rabeprazole—Tachycardia—Doxorubicin—bone cancer	0.00011	0.00058	CcSEcCtD
Rabeprazole—Paraesthesia—Epirubicin—bone cancer	0.000109	0.000577	CcSEcCtD
Rabeprazole—Hyperhidrosis—Doxorubicin—bone cancer	0.000109	0.000575	CcSEcCtD
Rabeprazole—Dyspnoea—Epirubicin—bone cancer	0.000108	0.000573	CcSEcCtD
Rabeprazole—Somnolence—Epirubicin—bone cancer	0.000108	0.000571	CcSEcCtD
Rabeprazole—Anorexia—Doxorubicin—bone cancer	0.000107	0.000567	CcSEcCtD
Rabeprazole—Feeling abnormal—Methotrexate—bone cancer	0.000107	0.000566	CcSEcCtD
Rabeprazole—Dyspepsia—Epirubicin—bone cancer	0.000107	0.000566	CcSEcCtD
Rabeprazole—CYP1A1—Tryptophan metabolism—MDM2—bone cancer	0.000107	0.00329	CbGpPWpGaD
Rabeprazole—Gastrointestinal pain—Methotrexate—bone cancer	0.000106	0.000561	CcSEcCtD
Rabeprazole—Decreased appetite—Epirubicin—bone cancer	0.000106	0.000559	CcSEcCtD
Rabeprazole—Hypotension—Doxorubicin—bone cancer	0.000105	0.000556	CcSEcCtD
Rabeprazole—Pain—Epirubicin—bone cancer	0.000104	0.00055	CcSEcCtD
Rabeprazole—Constipation—Epirubicin—bone cancer	0.000104	0.00055	CcSEcCtD
Rabeprazole—Urticaria—Methotrexate—bone cancer	0.000103	0.000545	CcSEcCtD
Rabeprazole—CYP1A1—Aryl Hydrocarbon Receptor—PTGS2—bone cancer	0.000103	0.00317	CbGpPWpGaD
Rabeprazole—ABCG2—HIF-1-alpha transcription factor network—JUN—bone cancer	0.000103	0.00316	CbGpPWpGaD
Rabeprazole—Abdominal pain—Methotrexate—bone cancer	0.000103	0.000543	CcSEcCtD
Rabeprazole—Body temperature increased—Methotrexate—bone cancer	0.000103	0.000543	CcSEcCtD
Rabeprazole—Musculoskeletal discomfort—Doxorubicin—bone cancer	0.000102	0.000542	CcSEcCtD
Rabeprazole—Insomnia—Doxorubicin—bone cancer	0.000102	0.000538	CcSEcCtD
Rabeprazole—Paraesthesia—Doxorubicin—bone cancer	0.000101	0.000534	CcSEcCtD
Rabeprazole—Dyspnoea—Doxorubicin—bone cancer	0.0001	0.00053	CcSEcCtD
Rabeprazole—Feeling abnormal—Epirubicin—bone cancer	0.0001	0.00053	CcSEcCtD
Rabeprazole—Somnolence—Doxorubicin—bone cancer	0.0001	0.000529	CcSEcCtD
Rabeprazole—Gastrointestinal pain—Epirubicin—bone cancer	9.94e-05	0.000525	CcSEcCtD
Rabeprazole—Dyspepsia—Doxorubicin—bone cancer	9.9e-05	0.000523	CcSEcCtD
Rabeprazole—Decreased appetite—Doxorubicin—bone cancer	9.78e-05	0.000517	CcSEcCtD
Rabeprazole—CYP1A2—Phase 1 - Functionalization of compounds—CYP3A4—bone cancer	9.72e-05	0.00299	CbGpPWpGaD
Rabeprazole—Urticaria—Epirubicin—bone cancer	9.66e-05	0.00051	CcSEcCtD
Rabeprazole—CYP1A1—Arachidonic acid metabolism—PTGS2—bone cancer	9.65e-05	0.00296	CbGpPWpGaD
Rabeprazole—Pain—Doxorubicin—bone cancer	9.62e-05	0.000508	CcSEcCtD
Rabeprazole—Constipation—Doxorubicin—bone cancer	9.62e-05	0.000508	CcSEcCtD
Rabeprazole—Abdominal pain—Epirubicin—bone cancer	9.61e-05	0.000508	CcSEcCtD
Rabeprazole—Body temperature increased—Epirubicin—bone cancer	9.61e-05	0.000508	CcSEcCtD
Rabeprazole—Hypersensitivity—Methotrexate—bone cancer	9.57e-05	0.000506	CcSEcCtD
Rabeprazole—Asthenia—Methotrexate—bone cancer	9.32e-05	0.000493	CcSEcCtD
Rabeprazole—CYP1A1—Aryl Hydrocarbon Receptor Pathway—JUN—bone cancer	9.3e-05	0.00286	CbGpPWpGaD
Rabeprazole—Feeling abnormal—Doxorubicin—bone cancer	9.27e-05	0.00049	CcSEcCtD
Rabeprazole—Gastrointestinal pain—Doxorubicin—bone cancer	9.2e-05	0.000486	CcSEcCtD
Rabeprazole—Pruritus—Methotrexate—bone cancer	9.19e-05	0.000486	CcSEcCtD
Rabeprazole—ABCG2—Transmembrane transport of small molecules—TUBB4B—bone cancer	9.18e-05	0.00282	CbGpPWpGaD
Rabeprazole—Hypersensitivity—Epirubicin—bone cancer	8.96e-05	0.000473	CcSEcCtD
Rabeprazole—Urticaria—Doxorubicin—bone cancer	8.94e-05	0.000472	CcSEcCtD
Rabeprazole—Abdominal pain—Doxorubicin—bone cancer	8.89e-05	0.00047	CcSEcCtD
Rabeprazole—Body temperature increased—Doxorubicin—bone cancer	8.89e-05	0.00047	CcSEcCtD
Rabeprazole—Diarrhoea—Methotrexate—bone cancer	8.89e-05	0.00047	CcSEcCtD
Rabeprazole—Asthenia—Epirubicin—bone cancer	8.72e-05	0.000461	CcSEcCtD
Rabeprazole—Pruritus—Epirubicin—bone cancer	8.6e-05	0.000455	CcSEcCtD
Rabeprazole—Dizziness—Methotrexate—bone cancer	8.59e-05	0.000454	CcSEcCtD
Rabeprazole—Diarrhoea—Epirubicin—bone cancer	8.32e-05	0.00044	CcSEcCtD
Rabeprazole—Hypersensitivity—Doxorubicin—bone cancer	8.29e-05	0.000438	CcSEcCtD
Rabeprazole—Vomiting—Methotrexate—bone cancer	8.26e-05	0.000437	CcSEcCtD
Rabeprazole—Rash—Methotrexate—bone cancer	8.19e-05	0.000433	CcSEcCtD
Rabeprazole—Dermatitis—Methotrexate—bone cancer	8.18e-05	0.000433	CcSEcCtD
Rabeprazole—Headache—Methotrexate—bone cancer	8.14e-05	0.00043	CcSEcCtD
Rabeprazole—CYP1A1—Biological oxidations—CYP3A4—bone cancer	8.1e-05	0.00249	CbGpPWpGaD
Rabeprazole—Asthenia—Doxorubicin—bone cancer	8.07e-05	0.000427	CcSEcCtD
Rabeprazole—Dizziness—Epirubicin—bone cancer	8.04e-05	0.000425	CcSEcCtD
Rabeprazole—CYP1A2—Aryl Hydrocarbon Receptor—RB1—bone cancer	8e-05	0.00246	CbGpPWpGaD
Rabeprazole—CYP1A1—Metapathway biotransformation—CYP3A4—bone cancer	7.99e-05	0.00246	CbGpPWpGaD
Rabeprazole—Pruritus—Doxorubicin—bone cancer	7.96e-05	0.000421	CcSEcCtD
Rabeprazole—ABCG2—Transmembrane transport of small molecules—TUBB2A—bone cancer	7.92e-05	0.00243	CbGpPWpGaD
Rabeprazole—CYP2C19—Arachidonic acid metabolism—PTGS2—bone cancer	7.89e-05	0.00243	CbGpPWpGaD
Rabeprazole—Vomiting—Epirubicin—bone cancer	7.73e-05	0.000409	CcSEcCtD
Rabeprazole—Nausea—Methotrexate—bone cancer	7.72e-05	0.000408	CcSEcCtD
Rabeprazole—Diarrhoea—Doxorubicin—bone cancer	7.7e-05	0.000407	CcSEcCtD
Rabeprazole—Rash—Epirubicin—bone cancer	7.67e-05	0.000405	CcSEcCtD
Rabeprazole—Dermatitis—Epirubicin—bone cancer	7.66e-05	0.000405	CcSEcCtD
Rabeprazole—Headache—Epirubicin—bone cancer	7.62e-05	0.000403	CcSEcCtD
Rabeprazole—CYP1A2—Phase II conjugation—GSTP1—bone cancer	7.55e-05	0.00232	CbGpPWpGaD
Rabeprazole—Dizziness—Doxorubicin—bone cancer	7.44e-05	0.000393	CcSEcCtD
Rabeprazole—CYP1A1—Aryl Hydrocarbon Receptor Pathway—EGFR—bone cancer	7.31e-05	0.00225	CbGpPWpGaD
Rabeprazole—CYP1A1—Aryl Hydrocarbon Receptor—EGFR—bone cancer	7.31e-05	0.00225	CbGpPWpGaD
Rabeprazole—Nausea—Epirubicin—bone cancer	7.22e-05	0.000382	CcSEcCtD
Rabeprazole—CYP2C9—Arachidonic acid metabolism—PTGS2—bone cancer	7.2e-05	0.00221	CbGpPWpGaD
Rabeprazole—ABCG2—Metabolism—NDUFA12—bone cancer	7.17e-05	0.00221	CbGpPWpGaD
Rabeprazole—Vomiting—Doxorubicin—bone cancer	7.15e-05	0.000378	CcSEcCtD
Rabeprazole—Rash—Doxorubicin—bone cancer	7.09e-05	0.000375	CcSEcCtD
Rabeprazole—Dermatitis—Doxorubicin—bone cancer	7.09e-05	0.000375	CcSEcCtD
Rabeprazole—Headache—Doxorubicin—bone cancer	7.05e-05	0.000372	CcSEcCtD
Rabeprazole—CYP1A1—Biological oxidations—GSTP1—bone cancer	6.93e-05	0.00213	CbGpPWpGaD
Rabeprazole—CYP1A1—Metapathway biotransformation—GSTP1—bone cancer	6.83e-05	0.0021	CbGpPWpGaD
Rabeprazole—CYP1A2—Tryptophan metabolism—MDM2—bone cancer	6.82e-05	0.0021	CbGpPWpGaD
Rabeprazole—Nausea—Doxorubicin—bone cancer	6.68e-05	0.000353	CcSEcCtD
Rabeprazole—CYP2C19—Biological oxidations—CYP3A4—bone cancer	6.63e-05	0.00204	CbGpPWpGaD
Rabeprazole—CYP1A2—Aryl Hydrocarbon Receptor—PTGS2—bone cancer	6.57e-05	0.00202	CbGpPWpGaD
Rabeprazole—CYP2C19—Metapathway biotransformation—CYP3A4—bone cancer	6.54e-05	0.00201	CbGpPWpGaD
Rabeprazole—CYP1A2—Arachidonic acid metabolism—PTGS2—bone cancer	6.15e-05	0.00189	CbGpPWpGaD
Rabeprazole—CYP2D6—Biological oxidations—CYP3A4—bone cancer	6.1e-05	0.00187	CbGpPWpGaD
Rabeprazole—CYP2C9—Biological oxidations—CYP3A4—bone cancer	6.05e-05	0.00186	CbGpPWpGaD
Rabeprazole—CYP2D6—Metapathway biotransformation—CYP3A4—bone cancer	6.01e-05	0.00185	CbGpPWpGaD
Rabeprazole—CYP2C9—Metapathway biotransformation—CYP3A4—bone cancer	5.96e-05	0.00183	CbGpPWpGaD
Rabeprazole—ABCG2—Metabolism—NT5C3A—bone cancer	5.94e-05	0.00183	CbGpPWpGaD
Rabeprazole—CYP1A2—Aryl Hydrocarbon Receptor Pathway—JUN—bone cancer	5.93e-05	0.00182	CbGpPWpGaD
Rabeprazole—CYP2C19—Biological oxidations—GSTP1—bone cancer	5.67e-05	0.00174	CbGpPWpGaD
Rabeprazole—CYP2C19—Metapathway biotransformation—GSTP1—bone cancer	5.59e-05	0.00172	CbGpPWpGaD
Rabeprazole—CYP3A4—Tryptophan metabolism—MDM2—bone cancer	5.26e-05	0.00162	CbGpPWpGaD
Rabeprazole—CYP2D6—Biological oxidations—GSTP1—bone cancer	5.22e-05	0.0016	CbGpPWpGaD
Rabeprazole—CYP2C9—Biological oxidations—GSTP1—bone cancer	5.17e-05	0.00159	CbGpPWpGaD
Rabeprazole—CYP1A2—Biological oxidations—CYP3A4—bone cancer	5.17e-05	0.00159	CbGpPWpGaD
Rabeprazole—CYP2D6—Metapathway biotransformation—GSTP1—bone cancer	5.14e-05	0.00158	CbGpPWpGaD
Rabeprazole—CYP2C9—Metapathway biotransformation—GSTP1—bone cancer	5.1e-05	0.00157	CbGpPWpGaD
Rabeprazole—CYP1A2—Metapathway biotransformation—CYP3A4—bone cancer	5.09e-05	0.00157	CbGpPWpGaD
Rabeprazole—CYP1A1—Metabolism—NDUFA12—bone cancer	4.86e-05	0.00149	CbGpPWpGaD
Rabeprazole—CYP1A2—Aryl Hydrocarbon Receptor Pathway—EGFR—bone cancer	4.66e-05	0.00143	CbGpPWpGaD
Rabeprazole—CYP1A2—Aryl Hydrocarbon Receptor—EGFR—bone cancer	4.66e-05	0.00143	CbGpPWpGaD
Rabeprazole—CYP1A2—Biological oxidations—GSTP1—bone cancer	4.42e-05	0.00136	CbGpPWpGaD
Rabeprazole—CYP1A2—Metapathway biotransformation—GSTP1—bone cancer	4.36e-05	0.00134	CbGpPWpGaD
Rabeprazole—CYP1A1—Metabolism—NT5C3A—bone cancer	4.02e-05	0.00124	CbGpPWpGaD
Rabeprazole—CYP2C19—Metabolism—NDUFA12—bone cancer	3.97e-05	0.00122	CbGpPWpGaD
Rabeprazole—CYP2D6—Metabolism—NDUFA12—bone cancer	3.66e-05	0.00112	CbGpPWpGaD
Rabeprazole—CYP2C9—Metabolism—NDUFA12—bone cancer	3.62e-05	0.00111	CbGpPWpGaD
Rabeprazole—CYP3A4—Biological oxidations—GSTP1—bone cancer	3.41e-05	0.00105	CbGpPWpGaD
Rabeprazole—CYP3A4—Metapathway biotransformation—GSTP1—bone cancer	3.36e-05	0.00103	CbGpPWpGaD
Rabeprazole—CYP2C19—Metabolism—NT5C3A—bone cancer	3.29e-05	0.00101	CbGpPWpGaD
Rabeprazole—CYP1A2—Metabolism—NDUFA12—bone cancer	3.1e-05	0.000952	CbGpPWpGaD
Rabeprazole—CYP2D6—Metabolism—NT5C3A—bone cancer	3.03e-05	0.000931	CbGpPWpGaD
Rabeprazole—CYP2C9—Metabolism—NT5C3A—bone cancer	3e-05	0.000923	CbGpPWpGaD
Rabeprazole—ABCG2—Metabolism—ENO2—bone cancer	2.6e-05	0.0008	CbGpPWpGaD
Rabeprazole—CYP1A2—Metabolism—NT5C3A—bone cancer	2.57e-05	0.000789	CbGpPWpGaD
Rabeprazole—ABCG2—Metabolism—DHFR—bone cancer	2.42e-05	0.000743	CbGpPWpGaD
Rabeprazole—CYP3A4—Metabolism—NDUFA12—bone cancer	2.39e-05	0.000735	CbGpPWpGaD
Rabeprazole—ABCG2—Metabolism—GNA11—bone cancer	2.26e-05	0.000694	CbGpPWpGaD
Rabeprazole—ABCG2—Metabolism—CYP3A4—bone cancer	2.05e-05	0.000629	CbGpPWpGaD
Rabeprazole—CYP3A4—Metabolism—NT5C3A—bone cancer	1.98e-05	0.000609	CbGpPWpGaD
Rabeprazole—CYP1A1—Metabolism—ENO2—bone cancer	1.76e-05	0.000542	CbGpPWpGaD
Rabeprazole—ABCG2—Metabolism—GSTP1—bone cancer	1.75e-05	0.000538	CbGpPWpGaD
Rabeprazole—CYP1A1—Metabolism—DHFR—bone cancer	1.64e-05	0.000503	CbGpPWpGaD
Rabeprazole—CYP1A1—Metabolism—GNA11—bone cancer	1.53e-05	0.00047	CbGpPWpGaD
Rabeprazole—CYP2C19—Metabolism—ENO2—bone cancer	1.44e-05	0.000443	CbGpPWpGaD
Rabeprazole—CYP1A1—Metabolism—CYP3A4—bone cancer	1.39e-05	0.000426	CbGpPWpGaD
Rabeprazole—CYP1A1—Metabolism of lipids and lipoproteins—PTGS2—bone cancer	1.38e-05	0.000424	CbGpPWpGaD
Rabeprazole—CYP2C19—Metabolism—DHFR—bone cancer	1.34e-05	0.000411	CbGpPWpGaD
Rabeprazole—CYP2D6—Metabolism—ENO2—bone cancer	1.33e-05	0.000408	CbGpPWpGaD
Rabeprazole—CYP2C9—Metabolism—ENO2—bone cancer	1.32e-05	0.000404	CbGpPWpGaD
Rabeprazole—CYP2C19—Metabolism—GNA11—bone cancer	1.25e-05	0.000384	CbGpPWpGaD
Rabeprazole—CYP2D6—Metabolism—DHFR—bone cancer	1.23e-05	0.000378	CbGpPWpGaD
Rabeprazole—CYP2C9—Metabolism—DHFR—bone cancer	1.22e-05	0.000375	CbGpPWpGaD
Rabeprazole—CYP1A1—Metabolism—GSTP1—bone cancer	1.18e-05	0.000364	CbGpPWpGaD
Rabeprazole—CYP2D6—Metabolism—GNA11—bone cancer	1.15e-05	0.000354	CbGpPWpGaD
Rabeprazole—CYP2C9—Metabolism—GNA11—bone cancer	1.14e-05	0.000351	CbGpPWpGaD
Rabeprazole—CYP2C19—Metabolism—CYP3A4—bone cancer	1.13e-05	0.000349	CbGpPWpGaD
Rabeprazole—CYP2C19—Metabolism of lipids and lipoproteins—PTGS2—bone cancer	1.13e-05	0.000347	CbGpPWpGaD
Rabeprazole—CYP1A2—Metabolism—ENO2—bone cancer	1.12e-05	0.000345	CbGpPWpGaD
Rabeprazole—CYP2D6—Metabolism—CYP3A4—bone cancer	1.04e-05	0.000321	CbGpPWpGaD
Rabeprazole—CYP1A2—Metabolism—DHFR—bone cancer	1.04e-05	0.000321	CbGpPWpGaD
Rabeprazole—CYP2C9—Metabolism—CYP3A4—bone cancer	1.03e-05	0.000318	CbGpPWpGaD
Rabeprazole—CYP2C9—Metabolism of lipids and lipoproteins—PTGS2—bone cancer	1.03e-05	0.000316	CbGpPWpGaD
Rabeprazole—CYP1A2—Metabolism—GNA11—bone cancer	9.74e-06	0.0003	CbGpPWpGaD
Rabeprazole—CYP2C19—Metabolism—GSTP1—bone cancer	9.7e-06	0.000298	CbGpPWpGaD
Rabeprazole—ABCG2—Metabolism—PTGS2—bone cancer	9.07e-06	0.000279	CbGpPWpGaD
Rabeprazole—CYP2D6—Metabolism—GSTP1—bone cancer	8.92e-06	0.000274	CbGpPWpGaD
Rabeprazole—CYP2C9—Metabolism—GSTP1—bone cancer	8.84e-06	0.000272	CbGpPWpGaD
Rabeprazole—CYP1A2—Metabolism—CYP3A4—bone cancer	8.83e-06	0.000272	CbGpPWpGaD
Rabeprazole—CYP1A2—Metabolism of lipids and lipoproteins—PTGS2—bone cancer	8.79e-06	0.00027	CbGpPWpGaD
Rabeprazole—CYP3A4—Metabolism—ENO2—bone cancer	8.67e-06	0.000267	CbGpPWpGaD
Rabeprazole—CYP3A4—Metabolism—DHFR—bone cancer	8.05e-06	0.000247	CbGpPWpGaD
Rabeprazole—CYP1A2—Metabolism—GSTP1—bone cancer	7.56e-06	0.000232	CbGpPWpGaD
Rabeprazole—CYP3A4—Metabolism—GNA11—bone cancer	7.52e-06	0.000231	CbGpPWpGaD
Rabeprazole—CYP1A1—Metabolism—PTGS2—bone cancer	6.14e-06	0.000189	CbGpPWpGaD
Rabeprazole—CYP3A4—Metabolism—GSTP1—bone cancer	5.83e-06	0.000179	CbGpPWpGaD
Rabeprazole—CYP2C19—Metabolism—PTGS2—bone cancer	5.02e-06	0.000154	CbGpPWpGaD
Rabeprazole—CYP2D6—Metabolism—PTGS2—bone cancer	4.62e-06	0.000142	CbGpPWpGaD
Rabeprazole—CYP2C9—Metabolism—PTGS2—bone cancer	4.58e-06	0.000141	CbGpPWpGaD
Rabeprazole—CYP1A2—Metabolism—PTGS2—bone cancer	3.91e-06	0.00012	CbGpPWpGaD
Rabeprazole—CYP3A4—Metabolism—PTGS2—bone cancer	3.02e-06	9.29e-05	CbGpPWpGaD
